Rfg Advisory, LLC Crispr Therapeutics Ag Transaction History

Rfg Advisory, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$110.2 - $156.64 $142,047 - $201,908	-1,289 Closed	0 $0
Q2 2021 Jul 29, 2021	BUY	$100.84 - $161.89 $129,982 - $208,676	1,289 New	1,289 $209,000
Q1 2021 Apr 19, 2021	SELL	$110.72 - $210.04 $374,676 - $710,775	-3,384 Closed	0 $0
Q4 2020 Feb 02, 2021	SELL	$79.67 - $173.23 $40,631 - $88,347	-510 Reduced 13.1%	3,384 $656,000
Q3 2020 Oct 13, 2020	BUY	$78.5 - $100.64 $69,551 - $89,167	886 Added 29.45%	3,894 $326,000
Q2 2020 Aug 03, 2020	BUY	$38.5 - $76.05 $115,808 - $228,758	3,008 New	3,008 $221,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Rfg Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Rfg Advisory, LLC with notifications on news.